News
ATRA
--
0.00%
--
Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...
BusinessWire - BZX · 3d ago
Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoim...
BusinessWire · 3d ago
Lymphoproliferative Disorder Treatment Market (2020-2028) | Potential growth, attractive valuation makes a long-term investment By Top Key Players
Jan 19, 2021 (AmericaNewsHour) -- Research Nester released a report titled "Lymphoproliferative Disorder Treatment: Global Demand Analysis & Opportunity...
AmericaNewsHour · 4d ago
8-K: Atara Biotherapeutics, Inc.
(EDGAR Online via COMTEX) -- DE false 0001604464 0001604464 2021-01-11 2021-01-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/12 05:51
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atara Biotherapeutics (ATRA), Humanigen (HGEN) and Nevro Crop (NVRO)
SmarterAnalyst · 01/11 14:38
Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the "Company"), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic canc...
Business Wire · 01/10 21:06
Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference
--Atara is well-positioned for success in anticipated tab-cel(R) regulatory submissions, approval and launch
BusinessWire · 01/10 18:06
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoi...
Business Wire · 01/06 13:30
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoi...
BusinessWire · 01/06 10:30
Atara Says Has Not Yet Initiated The Biologics License Application For Tab-Cel; Remains On Track To Complete Filing In Q3, Says 'awaiting a procedural decision from the FDA related to how the historical non-pivotal data should be presented'
Company to Host Conference Call on January 4th at 8:30 a.m. EST Atara Biotherapeutics, Inc. (NASDAQ:ATRA, the ", Company", )))), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell
Benzinga · 01/04 12:38
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the "Company"), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cance...
Business Wire · 01/04 12:30
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel(R) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the "Company"), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cance...
BusinessWire · 01/04 09:30
Atara Biotherape Set to Possibly Rebound After Yesterday's Selloff of 1.56%
Atara Biotherape (NASDAQ:ATRA) traded in a range yesterday that spanned from a low of $19.85 to a high of $20.37. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $20.15 on volume of 222,000 shares. Often times after ...
Comtex SmarTrend(R) · 12/31/2020 17:40
The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks
Biotech stocks advanced for a fifth straight week in thin holiday trading. The gains, however, were more modest amid worries concerning the emergence of a new strain of coronavirus in the U.K. The news flow of the week comprised mixed clinical trial readouts, COVID-19 drug and vaccine announcements, a few M&A announcements and a small-ticket IPO.
Benzinga · 12/26/2020 14:15
Atara Biotherape Has Returned 51.0% Since SmarTrend Recommendation (ATRA)
SmarTrend identified an Uptrend for Atara Biotherape (NASDAQ:ATRA) on October 8th, 2020 at $14.57. In approximately 2 months, Atara Biotherape has returned 50.98% as of today's recent price of $21.99.
Comtex SmarTrend(R) · 12/18/2020 05:20
Uptrend Call Working As Atara Biotherape Stock Rises 58.3% (ATRA)
SmarTrend identified an Uptrend for Atara Biotherape (NASDAQ:ATRA) on October 8th, 2020 at $14.57. In approximately 2 months, Atara Biotherape has returned 58.32% as of today's recent price of $23.06.
Comtex SmarTrend(R) · 12/10/2020 05:16
Atara Bio prices $175M equity offering
Atara Biotherapeutics (ATRA) has priced its public offering of 5,102,041 common shares at $24.50/share and, to certain investors, pre-funded warrants to purchase 2,040,816 shares of its common stock at $24.4999/warrant.The
Seekingalpha · 12/09/2020 11:31
Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoim...
Business Wire · 12/09/2020 02:26
Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoim...
BusinessWire · 12/08/2020 23:26
The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 7)
Benzinga · 12/08/2020 13:03
Webull provides a variety of real-time ATRA stock news. You can receive the latest news about Atara Biotherapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATRA
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.
More